Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 1, 2015
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2015 on Wednesday, October...
-
Sep 29, 2015
Boston Scientific Corporation (NYSE: BSX) announced today the launch of the Captivator™ EMR Device for Endoscopic Mucosal Resection (EMR), a minimally invasive alternative to an esophagectomy, a...
-
Sep 28, 2015MAJESTIC Trial Data Support Strong Safety Profile with Low Target Lesion Revascularization Rate
New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more...
-
Sep 10, 2015System Includes First Directional Lead with Current Steering and Expanded Programming Flexibility
Boston Scientific (NYSE: BSX) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting...
-
Sep 2, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2015 Morgan Stanley Global Healthcare Conference on September 17, in New York City. Mike Mahoney, chief executive...
-
Aug 26, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2015 Wells Fargo Healthcare Conference on September 9 in Boston, MA. Mike Mahoney, chief executive officer, and Dan...
-
Aug 24, 2015Updated labeling allows backwards-compatibility for MRI scans for the industry's longest-lasting ICD and CRT-D systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable...
-
Aug 19, 2015U.S. Launch Underway for Therapy Designed to Treat Peripheral Artery Disease
Boston Scientific Corporation (NYSE: BSX) has received Food and Drug Administration (FDA) approval for the Innova™ Vascular Self-Expanding Stent System, an advanced treatment option for patients...
-
Aug 4, 2015
Boston Scientific Corporation (NYSE: BSX) has closed on the previously announced agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to purchase American Medical Systems' (AMS) Men's...
-
Aug 3, 2015Strategic alliance to expand Boston Scientific portfolio of remote monitoring solutions
Boston Scientific (NYSE: BSX) has become a significant shareholder and will become the exclusive worldwide sales and marketing representative for Preventice Solutions for cardiology-related...
-
Jul 23, 2015
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.843 billion during the second quarter ended June 30, 2015, compared to the company's guidance range for the quarter of $1.800 to...
-
Jul 22, 2015First Guidewire Designed Specifically for TAVI/R Now Sized for Smaller Ventricles
MARLBOROUGH, Mass. (July 22, 2015) – Boston Scientific (NYSE: BSX) announces CE Mark and FDA clearance for the Safari2™ Pre-Shaped Guidewire, a new and enhanced version of the Safari...
-
Jul 20, 2015First Patients Enrolled in the FAST Feasibility Study
Boston Scientific (NYSE: BSX) has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective,...
-
Jul 15, 2015
Boston Scientific Corporation (NYSE: BSX) announces the election of Donna A. James to its board of directors, effective immediately. Donna A. James is the founder and managing director of Lardon &...
-
Jul 9, 2015
Boston Scientific Corporation (NYSE: BSX) announces that Bronchial Thermoplasty (BT) delivered by the Alair™ System has received support from the American College of Allergy, Asthma and...
-
Jul 1, 2015
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2015 on Thursday, July 23, 2015 at
-
Jun 22, 2015
Boston Scientific (NYSE: BSX) has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for...
-
Jun 10, 2015
Boston Scientific Corporation (NYSE: BSX) presented new data demonstrating that the Precision Spectra™ Spinal Cord Stimulator (SCS) System provided 1.5 times better overall pain relief and 2...
-
Jun 4, 2015World's Smallest 16-Contact High-Capacity Primary Cell Device Expands Spinal Cord Stimulator System Offering
Boston Scientific announces the European launch of the Precision Novi™ Spinal Cord Stimulator (SCS) System at the International Neuromodulation Society in Montreal, Canada. The 16-contact...
-
May 26, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs 36th Annual Global Healthcare Conference on June 9 in Rancho Palos Verdes, CA. Dan Brennan, executive...
-
May 20, 2015Compelling Results Presented at EuroPCR 2015 Add to Growing Body of Evidence Supporting Performance and Safety
A new study evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System demonstrated an extremely low rate of paravalvular aortic regurgitation (leakage) for a transcatheter aortic...
-
May 19, 2015Additional Data from EVOLVE II Pivotal Trial Demonstrate Safety and Performance in Patients with Diabetes at One Year
Boston Scientific (NYSE: BSX) reported positive, long-term data from the EVOLVE Trial of the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System, with no...
-
May 12, 2015
Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.85 billion aggregate principal amount of its senior notes under the company's shelf registration statement. The public...
-
May 11, 2015
Boston Scientific (NYSE: BSX) today announced that key data from 42 abstracts will be featured at the 36th Annual Scientific Sessions of the Heart Rhythm Society (HRS) in Boston on May 13-16....
-
May 7, 2015
Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.85 billion aggregate principal amount of its senior notes under the company's shelf registration...